HSD17B13 siRNA (Argo Biopharma)

N/A

Report date: 2024/04/19 11:27:08
NME

Base Information

Drug NameHSD17B13 siRNA (Argo Biopharma)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of Action17-beta-hydroxysteroid dehydrogenase 13 Expression Inhibitors
Targets17-beta-hydroxysteroid dehydrogenase 13
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Argo Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Argo Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A